Program Announcement for the Defense Health Agency

Toxic Exposures Research Program Translational Research Award

Funding Opportunity Number: HT942526TERPTRA

Pre-Application Due: August 19, 2026

Application Due: November 19, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click ⓘ to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan.

Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP TRA includes a **Partnering Principal Investigator Option (PPIO).** One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising ideas into clinical applications. Partnering should significantly advance the research beyond what would be possible through individual efforts.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $6.0M to fund approximately four Translational Research Award applications with total cost caps of $1.5M per award. The maximum period of performance is 3 years. It is anticipated that awards made from this fiscal year 2026 (FY26) funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Preproposal) Submission Deadline:** 5:00 p.m. Eastern Time (ET), August 19, 2026
- **Invitation to Submit an Application:** October 1, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, November 19, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, November 24, 2026
- **Peer Review:** January 2027
- **Programmatic Review:** March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526TERPTRA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Independent investigators at all career levels may be named by their organizations as the Principal Investigator (PI) or the partnering PI on the application.

Partnering PI Option (PPIO): One initiating PI and one partnering PI may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.

Individuals in a mentored position (e.g. postdoctoral fellows, clinical fellows) are not considered independent investigators.

Independent investigators affiliated with an eligible organization are eligible to be named as the PI or the Partnering PI on the application, regardless of ethnicity, nationality or citizenship status.

An investigator may be named on only one TERP application as a PI.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Toxic Exposures Research Program (TERP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the TERP in 2022 to provide solutions toward the prevention, diagnosis, treatment, and mechanistic understanding of the adverse health outcomes associated with a broad range of military-related toxic exposures. Appropriations for the TERP from FY22 through FY25 totaled $105 million (M). The FY26 appropriation is $15M.

The vision of the TERP is to improve the health and quality of life and mitigate risks for those impacted by military-related toxic exposures. The mission of the TERP is to fund research to understand and provide solutions to prevent, diagnose, and treat the health outcomes associated with military-related toxic exposures impacting Service Members, Veterans, their Families and the public.

Impactful and highly relevant research will be hypothesis-driven and consider the health care needs of Service Members, their Families, Veterans, and/or the American public with symptoms, diseases, or conditions as a result of military-related toxic exposures and/or the need to minimize toxic exposures for military and civilian populations.

The TERP strongly encourages applicants to review Appendix 3, TERP Definitions, before writing and submitting their application.

The TERP encourages collaboration with DOW and/or U.S. Department of Veterans Affairs (VA) researchers and clinicians.

3.1. Award History

The TERP Translational Research Award (TRA) mechanism was first offered in FY22, with the Translational Research Partnership Award (which required partnership) being offered in FY25. Since FY22, 189 TRA applications (representing 380 potential awards) were received, and 20 applications (representing 39 awards) were recommended for funding.

3.2. Intent of the Translational Research Award

The intent of the FY26 TERP TRA is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies, and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science or vice versa in developing and implementing the research plan.

3.2.1. TERP Program Goals and Topic Areas

To meet the intent of the award mechanism, applicants to the TRA are required to address **at least one of the FY26 TERP program goals and at least one of the FY26 TERP topic areas.** Proposed research may be related to diseases, conditions, or symptoms supported by other

CDMRP programs; however, TRA applications must be relevant to military-related toxic exposures. Selection of the program goal(s) and topic area(s) is the responsibility of the applicant. Selection must be made during the pre-application submission process and addressed in detail in the full application submission.

Program Goals: *The FY26 TERP program goals are not listed in order of importance*. The bulleted items are provided for additional context on current program priorities and, while encouraged, these are not the only items that can be addressed by applications.

Predict and Prevent: *Identify strategies that can anticipate, identify, monitor, and prevent adverse effects of exposures to toxic substances.*

- Understand the full range of effects from military-related environmental and toxic exposures to aid in predicting/preventing the effects.
- Understand the mechanisms of multigenerational effects of military-related toxic exposures and the impact of these exposures on reproductive health to aid in predicting/preventing the effects.
- Identify biological and/or psychosocial variables and risk factors that can impact disease outcomes from toxic exposures.
- Develop, adapt, validate, or optimize monitoring, for example, personal devices to detect and characterize individual environmental exposures.

Diagnose: *Understand the clinical signs, symptoms, and outcomes associated with exposures; and predict disease progression to develop specific or improved diagnostics.*

- Understand complex, multi-exposure/physiological or nonchemical stressor (e.g., hormonal, sleep disorders, thermal stress) combinations, and how exposure impacts outcome.
- Identify behavioral factors (smoking, substance abuse, etc.), comorbidities, and pre-existing medical conditions that may impact exposure outcomes.
- Identify biomarkers of exposure to individual or multiple toxic substances alone or in combination with physiological/nonchemical stressors.
- Develop diagnostic screens/assays/devices for toxic exposures.

Treat: *Minimize symptoms and disease progression associated with exposures.*

- Develop new or improve existing therapeutics, treatments and strategies.
- Advance new therapeutics, treatments and strategies.
- Address the need for preclinical models that capture the adverse outcomes of human toxic exposures.

Topic Areas: *Topic areas are not listed in order of importance.*

- Neurotoxin Exposure
- Gulf War Illness (GWI) and Its Treatment
- Airborne Hazards and Burn Pits
- Other Military Service-Related Toxic Exposures in General, including Prophylactic Medications, Groundwater Contamination, Pesticides, Organophosphates, Toxic Industrial Chemicals, Materials, Metals and Minerals

3.2.2. TERP Additional Guidance

Studies focused on the following areas do NOT meet the intent of the FY26 TERP:

- Research data that are classified and/or research in which the anticipated outcomes may be classified or deemed sensitive to national security concerns.
- Chemical warfare agents categorized as fourth-generation agents or non-traditional agents.
- Biological Select Agents or Toxins.
- Anomalous Health Incidents, commonly referred to as Havana Syndrome.
- Directed energy weapons.
- Development of medical countermeasures or devices intended to diagnose, detect, prevent, or treat the immediate (point of injury) health effects of chemical weapons, biological, radiological or nuclear threats.
- Treatments or therapeutics for the immediate, adverse health effects of any exposure that would be administered in an acute care setting, i.e., role of care (ROC) 1 or ROC 2.
    - In the military health echelon/ROC, this generally refers to ROC 1 and ROC 2 described below:
        - ROC 1: Unit-level medical care, ranging from point of injury through battalion aid station.
        - ROC 2: Advanced trauma management and emergency medical treatment.
        - For more information on the military roles of care, refer to Chapter 2, "Roles of Medical Care (United States)," Emergency War Surgery, Fifth United States Edition, 2018, Borden Institute.

Studies focused on the following areas ARE permitted. *These examples are meant to inform prospective applicants in the context of the above exclusions and do not imply that these research areas are prioritized over any others within the scope of the FY26 TERP Program Goals and FY26 TERP Topic Areas.*

- Evaluation/treatment of long-term or chronic health impacts of traditional chemical weapons, including but not limited to the long-term effects of sub-lethal doses of sarin, soman, and sulfur mustard and Gulf War illness.
- Other long-term/chronic effects of military-related exposures that would be diagnosed or treated at a ROC 3 (field hospital) or ROC 4 (definitive care; fixed medical treatment facility) or beyond.

3.2.3. Key Elements for the TRA

- **Translational Potential:** Projects should integrate basic science and clinical observations to accelerate the movement of promising ideas in military-related toxic exposure research toward clinical applications including health care products, interventions, technologies, or clinical practice guidelines that are relevant to Service Members, their Families, Veterans and/or the American public. The application should also demonstrate the reciprocal transfer of information between basic and clinical scientists.

  Applications must clearly articulate three points along the translational research spectrum:

    - Where the field is now
    - Where the field will be after the successful completion of the proposed research project

- What the next step(s) will be after completion of the proposed project

- **Impact:** Applications should explain how the proposed research will have a significant impact on military-related toxic exposure research and/or patient care, with the intent to transition outcome(s)/product(s) (intellectual knowledge and/or tangible materiel) into clinical practice for Service Members, their Families, Veterans, and/or the American public who have been or could potentially be impacted by toxic exposures. Applications should demonstrate both the short- and long-term impacts, and how the successful completion of the proposed research will impact a critical problem or question in the field of research and/or patient care in at least one of the FY26 TERP Program Goals and at least one of the FY26 TERP Topic Areas.
- **Preliminary Data are Required:** Applications must include preliminary data (e.g., published works by the investigators, pilot data, peer-reviewed literature) to support feasibility of the study. Any unpublished preliminary data provided should originate from the laboratory of the PI(s) and/or a member(s) of the research team.
- **Partnering PI Option:** The TRA includes an option for the Initiating PI to collaborate with one Partnering PI in order to encourage applications that include meaningful and productive collaborations between investigators. The intent of this option is to support new or existing interdisciplinary partnerships, such as those between clinicians and research scientists that will accelerate the movement of promising ideas into clinical applications.

  One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Each PI is expected to bring a distinct contribution to the application, and the PIs' unique expertise, when combined as a partnership, should address the research question better than any one investigator could individually. The PIs should have appropriately balanced intellectual input into the design and conduct of the project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section 5.3, Submission Instructions.

3.2.4. Other Important Considerations for the TRA

Clinical trials are not allowed within this funding opportunity. TRA applications may include preclinical studies (including research involving animals) and/or *clinical research* involving human subjects, human anatomical substances, and human datasets, including correlative studies associated with an existing clinical trial.

For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research.

Applications proposing clinical trials may be submitted to the following FY26 TERP funding opportunity:

- Clinical Trial Award (Funding Opportunity Number HT942526TERPCTA)

It is the responsibility of the applicant to review the program announcement requirements and select the funding opportunity that aligns with the scope of the proposed research. Applications submitted under a mechanism that is not deemed appropriate for the type and scope of research requested will not be recommended for funding.

It is strongly encouraged that studies using human subjects, human anatomical substances, and/or datasets use relevant military and/or Veteran

populations/samples/datasets. Applicants are strongly encouraged to utilize objective data and measures to the maximum extent practicable. Applications not using military and/or Veteran populations/samples/datasets are strongly encouraged to provide justification for how the chosen populations/samples/datasets are relevant to military-related toxic exposures and will benefit Service Members, their Families and/or Veterans.

When applicable, the research team is encouraged to include both preclinical and clinical investigators.

Participation of at least one military or Veteran consumer as a member of the research team to contribute to the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project, is strongly encouraged.

- For the purposes of the FY26 TERP, a consumer is a person living with a disease, injury, or condition, or a family member or caregiver of a person impacted by a disease, injury, or condition associated with military-related toxic exposures. The consumer must be an active participant in an advocacy, outreach, or support organization; or, if military personnel on active duty, be approved to participate by their Commanding Officer.

Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE and ARRIVE guidelines 2.0.

Research Involving Animal Models: If the application proposes the use of animal models, consider the following:

- Pairing clinical populations to animal models in order to validate the clinical relevance and development of prevention, assessment, and treatment solutions is encouraged.
- For studies using animal models, the use of an established model is preferred unless there is a compelling scientific justification for the development or use of a new model.
- Proposed animal models should be well-justified, supported within the literature, and clearly align with clinical relevance.
- For studies proposing GWI research with animal models, a list of animal models funded by the former DOW CDMRP Gulf War Illness Research Program (GWIRP) is available at https://cdmrp.health.mil/gwirp/resources/amodels.

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Use of DOW or VA Resources: Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the VA and other federal government agencies are highly encouraged. These relationships can leverage knowledge, datasets, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

Resources for Data and/or Previously Collected Biospecimens: The TERP has provided Appendix 4 as a reference, and it is not an exhaustive list of all resources that may be

applicable to the proposed research. Researchers are not required to use any of the following limited examples provided or any one particular dataset. The TERP does not facilitate access to any of these resources and/or control the information presented on the websites.

Red Hill Health Impacts: *Applications proposing epidemiological research on health outcomes that may be associated with the 2021 fuel release at Red Hill Bulk Fuel Storage Facility, or jet fuel exposures more broadly, are allowed under this mechanism.*

In accordance with the National Defense Authorization Act for Fiscal Year 2024, Section 1092, the DOW conducted a feasibility assessment regarding potential Red Hill epidemiological health outcomes studies. This independent assessment emphasized that a variety of study scopes (i.e., population segments, types and pathways of exposure, health outcomes of interest) may be valuable and that the study design (i.e., cross-sectional or longitudinal; short-, medium-, or long-term; exposure-control or case-control) will depend on the associations being investigated. The DOW encourages use of existing registries and expects that all studies will define and recruit appropriate comparison/control groups as well as account for potential confounding variables. Researchers can find additional resources related to the incident, including registry information and preliminary studies in Appendix 4.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is **3** years.

Single PI Option:

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **$1.5M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Partnering PI Option:

Cost Cap: The combined total costs budgeted for the entire period of performance in the applications of the Initiating PI and the Partnering PI should not exceed **$1.5M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

A separate award will be made to each PI's organization.

The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly unless otherwise warranted and clearly justified.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for one investigator (Single PI Option) and/or for one investigator from each partnering application (PPIO) to attend one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 TERP TRA.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Clinical trial costs.

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

The PI or Initiating PI must submit the following pre-application components.

Upload documents as individual PDF files unless otherwise noted. Files must comply with the formatting guidelines listed in the GAI.

- **Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  The Preproposal Narrative should include the following:

  - **Background/Rationale:**
    - State the hypothesis of the proposed study and provide a brief explanation of the study rationale clearly articulating how the hypothesis and rationale are well-supported/justified.
  - **Specific Aims and Study Design:**
    - Concisely state the specific aims of the proposed study.
    - Briefly describe the experimental methods and approaches.
    - As applicable, succinctly describe the proposed model system(s) (cellular, animal etc.), human samples, human datasets and/or human subjects.
      - If the application will use human subjects, samples and/or datasets, indicate whether the proposed project will use military and/or Veteran populations/ samples/datasets OR how the chosen population/samples/datasets are relevant to military-related toxic exposures and will benefit Service Members, their Families and/or Veterans.
  - **Alignment:**
    - Describe how the proposed project addresses at least one FY26 TERP Program Goal and at least one FY26 TERP Topic Area.

- **Translational Potential:**
  - Describe how the proposed study will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications including health care products, interventions, technologies or clinical practice guidelines. Explain how the application will integrate basic science and clinical observations and allow for the reciprocal transfer of information between basic and clinical scientists.
  - Clearly articulate the following three points along the translational research spectrum:
    - Where the field is now.
    - Where the field will be after the successful completion of the proposed research project.
    - What the next step(s) will be after completion of the proposed project.
- **Impact and Military Relevance:**
  - State both the short- and long-term impacts and how the successful completion of the proposed research will advance the research field and ultimately lead to new treatments/therapeutics, diagnostic assays, or prevention strategies to improve the quality of life for those impacted by or likely to encounter toxic substances.
  - State how the proposed research is responsive to the health care needs of Service Members, their Families, and/or Veterans that have been or could potentially be exposed to military-related toxic exposures.
  - Describe how research findings could also benefit the general population.
- **Partnership *(only relevant for PPIO submissions)*:**
  - Briefly describe the interdisciplinary partnership and how the collaborative efforts will better address the research question.

- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application ***must be uploaded as individual files*** and are limited to the following:
  - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
  - **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.
  - **Key Personnel Biographical Sketches: *All biographical sketches should be uploaded as a single combined file.*** Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected**.**

Partnering PI Option: The CDMRP requires separate full application package submissions for the Initiating PI and the Partnering PI, even if the PIs are located within the same organization. The application submission process for the Partnering PI uses an abbreviated full application package.

4.3.1. Full Application Components for the PI or Initiating PI

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative (15-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed project in detail using the outline below.

  - **Background/Rationale:** Describe in detail the scientific rationale for the study. Applications must include preliminary data (e.g., published works by the investigators, pilot data, peer-reviewed literature) to support the feasibility of the study. Any unpublished preliminary data provided should originate from the laboratory of the PI(s) and/or a member(s) of the research team. The rationale should include a literature review that supports the development of the proposed project. The background section should clearly support the choice of the study variable and should explain the basis for the study questions and/or hypotheses. Provide a summary of relevant prior preclinical and/or clinical work, and distinguish how the proposed study differs from other relevant or recently completed research. State the relevance of the proposed research and the applicability of the anticipated findings to the intent of the mechanism and to at least one of the FY26 TERP Program Goals and at least one of the FY26 TERP Topic Areas.
  - **Hypothesis or Objective:** Clearly state the hypothesis or the objective(s).
  - **Specific Aims:** State and concisely explain the project's specific aims. These aims should agree with the aims and associated tasks described in Attachment 5, Statement of Work. If the proposed research project is part of a larger study, present only tasks that this TERP award would fund.
  - **Research Strategy and Feasibility:**
    - Describe the experimental design, methods, and models, including appropriate controls, in sufficient detail to allow for their appropriateness and feasibility to be

assessed. Identify how the research strategy and approaches will meet the project's goals and milestones.

- ❖ Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Details of the strategy for how sex will be considered as a biological variable will be required in Attachment 2.

- Provide justification for the approach/model that will be used to support the proposed studies.
  - ❖ If cell lines or animals are to be used, justify why the proposed cell line(s) or animal model(s) were chosen and discuss the model's clinical relevance to human biology (including but not limited to routes of human exposures, exposure dose, outcomes [human symptoms, diseases/conditions] associated with exposures, and the types of exposures potentially encountered). ***For animal studies, full details will be required in the Animal Research Plan (Attachment 9).***
  - ❖ If proposing a correlative study, specify how the proposed project complements the existing research efforts and provides additional relevant insight beyond the initial study design.
  - ❖ If human subjects, human biological samples, or datasets will be used, describe the study population and the appropriateness of the designated study population for the proposed study. ***Applicants are strongly encouraged to use relevant military and/or Veteran populations/ samples/datasets.*** Clearly state if studies will utilize human specimens or data that cannot be linked to a living individual and meet the requirements for exemption under 45 CFR 46.104(d)(4) of the Common Rule, Secondary Research for Which Consent is Not Required. ***For research involving human subjects, human biological samples, or datasets, full details will be required in the Human Subjects/Samples/Data Acquisition Plan (Attachment 10).***
- Describe the statistical model and data analysis plan, as applicable.
  - ❖ Provide a statistical sample size estimate and the method by which it was derived, including power analysis calculations, to demonstrate that the sample size is appropriate to meet the objectives of the study.
  - ❖ Explain the statistical methods/model that will be used for data analysis.
  - ❖ Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, and how outliers will be defined and managed, if applicable.
  - ❖ Describe the randomization and blinding/masking procedures for the study, and any other measures to be taken to minimize the effects of subjective bias, if applicable.
- Describe how the proposed project is feasible and will be completed within the proposed performance period.
- Address potential research challenges and pitfalls, and provide alternative methods and approaches.

- If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the GAI, Appendix 4, for additional considerations.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

  There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items.

  - **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
  - **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
  - **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.
  - **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
  - **Letters of Support (two-page limit per letter is recommended):** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI meets the eligibility criteria. If applicable, provide a letter of support signed by any consumer(s) participating on the research team to demonstrate their commitment to the proposed project. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.
  - **Sex as a Biological Variable Strategy (two-page limit is recommended):** If applicable, describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature,

preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

- **Research Sharing Plan:** Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

  Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

  Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Inclusion Enrollment Report *(if applicable; only required if clinical research is proposed)*:** Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the "Public Health Service (PHS) Inclusion Enrollment Report", a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement.
- **Quad Chart:** Provide a Quad Chart for the proposed project. The format for the Quad Chart is available on the eBRAP Funding Opportunities & Forms page.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project.
- **Hypothesis/Objective(s):** State the hypothesis and/or objective(s).
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Briefly describe the experimental design, including model system(s) and appropriate controls.

- **Impact:** Briefly describe how the proposed research will have a significant impact on toxic exposure research and/or patient care with the intent to transition outcomes into clinical practice for Service Members, their Families, Veterans, and/or the American public that have been, or could potentially be, impacted by military-related toxic exposures. State both the short- and long-term impacts, and how the proposed research will ultimately lead to new treatments/therapeutics, diagnostic assays, or prevention strategies that improve the quality of life for those impacted by or likely to encounter toxic substances.
- **Relevance to the TERP:** Applications should articulate how the proposed research is relevant to at least one of the FY26 TERP Program Goals and addresses at least one of the FY26 TERP Topic Areas.
- **Military Relevance:** State how the proposed research is responsive to the health care needs of Service Members, their Families, and/or Veterans that have been or could potentially be exposed to military-related toxic exposures. Describe how research findings could also benefit the general population.

○ **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

- Summarize the objectives and rationale for the proposed research.
- Describe the ultimate applicability of the research and how it addresses at least one of the FY26 TERP Program Goals and at least one of the FY26 TERP Topic Areas.
- Indicate what population(s) the research will help and how it will help them.
- Describe potential clinical applications, benefits and risks.
- Describe the projected timeline to achieve the expected patient-related outcome.
- Describe the likely contributions of the proposed research project to advance knowledge and lead to new treatments/therapeutics, diagnostic assays, or prediction and prevention strategies that improve the quality of life for individuals impacted by or likely to encounter toxic substances.
- Describe how the proposed project will impact the health and well-being of Service Members, their Families and/or Veterans.

○ **Attachment 5: Statement of Work (six-page limit): Upload as "SOW.pdf".**
Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

For applications submitted under the Partnering PI Option, each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and the Partnering PI should be clearly noted for each task.

The SOW should state the specific aims described in the Project Narrative and include a list of major tasks and subtasks that support the completion of the stated aims, including milestones for completing the aims during the period of performance. The SOW should

describe only the work for which funding is being requested by this application and as applicable:

- Include the name(s) of the key personnel for each study site/subaward site.
- Indicate the number (and type, if applicable) of research subjects (animal or human) and/or human anatomical samples projected or required for each task and at each site.
- Identify cell line(s) and commercial or organizational source(s) to be used.
- If applicable, indicate timelines required for regulatory approvals relevant to animal or human subjects research (e.g., local IACUC/IRB and federal ORRC approvals). Refer to the GAI, Appendix 6, for additional information regarding regulatory requirements.
- For studies with prospective accrual of human subjects, indicate quarterly enrollment targets. If applicable, indicate timelines and approvals required to obtain access to databases, repositories or other resources.

- **Attachment 6: Translation Statement (one-page limit): Upload as "Translation.pdf".** The ultimate goal of translational research is to move an observation forward into clinical application and accelerate the introduction of health care products, interventions, technologies, or clinical practice guidelines. Describe and justify how the proposed military-related toxic exposures research project is translational in nature, including how it will help to move an observation forward into clinical application and how it will allow for the reciprocal transfer of ideas between basic and clinical science.

  Clearly articulate three points along the translational research spectrum:

  - Where the field is now, including the current state of knowledge or practice.
  - Where the field will be after the successful completion of the proposed research project.
  - What the next step(s) will be after completion of the proposed project.

  Discuss the timeframes of specific translation pathways for the proposed outcome(s)/ product(s).

- **Attachment 7: Impact and Military Relevance (three-page limit): Upload as "Impact.pdf".** The Impact and Military Relevance must demonstrate how a successful outcome of the proposed research project will advance at least one of the FY26 TERP Program Goals and at least one of the FY26 TERP Topic Areas. ***The Impact and Military Relevance should be written in a manner that will be readily understood by readers without a background in science or medicine.***

  - Describe how a successful outcome of the proposed research project will reduce the burden (effects/outcomes, new exposures, etc.) of military-related toxic exposures for Service Members, their Families, Veterans and/or the American public.
  - **Describe the short-term impact:** Detail the anticipated outcome(s)/products (intellectual knowledge and/or tangible materiel) that will make important scientific advances and improve the understanding, prevention/prediction, diagnosis, and/or treatment of military-related toxic exposures.
  - **Describe the long-term impact:** Explain the anticipated long-term benefits from this research and how it will impact the field of study and/or the lives of relevant patient or

community populations. Discuss how the proposed materiel or knowledge product represents an improvement to currently available prevention strategies, treatments/ interventions, diagnostic approaches, devices, or clinical practice guidelines, if applicable.

- Discuss the near-term and long-term impact of the translation pathways for the proposed outcome(s)/product(s).
- Describe how the proposed effort is responsive to the health care needs and quality of life of Service Members, their Families and/or Veterans.
- Provide a description of how the knowledge, information, products, or technologies gained from the research could be implemented in a dual-use capacity to benefit the civilian population and address a military need, as appropriate.
- If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

- **Attachment 8: Post-Award Transition Plan (three-page limit): Upload as "Transition.pdf".** Describe the methods and strategies proposed to advance the anticipated research outcomes/products (intellectual knowledge and/or tangible materiel) to the next phase of development (clinical trials, commercialization, and/or delivery to the civilian or military market) after successful completion of the proposed effort. Applicants are encouraged to work with their organization's Technology Transfer Office (or equivalent) to develop the post-award transition plan.

  The post-award transition plan should include the components listed below, as appropriate and applicable to the research proposed.

  - A description of the anticipated outcomes/products expected upon completion of the proposed research efforts. Outcomes should be relevant, measurable, and include the intended end-user.
  - Provide a description of how the anticipated outcomes/products of the proposed research will be disseminated to both the scientific and consumer/stakeholder communities.
  - Details of the funding strategy that will be used to advance the outcomes to the next phase of development, commercialization (e.g., partners, funding opportunities to be applied for), and/or incorporation into patient care.
  - Provide a brief schedule and milestones for bringing the outcomes/products to the next phase of development (e.g., further research, clinical trials, commercialization/ transition to industry, delivery to the military or civilian market, incorporation into clinical practice, clearance/approval by a Regulatory Agency).
  - For knowledge products, include the development or modification of clinical practice guidelines/recommendations, provider training materials, patient brochures, clinical support tools, scientific journal publications, models, simulations, and other applications. (A "knowledge product" is a non-materiel product that aims to transition into medical practice, training, tools, or to support materiel solutions; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)
  - As appropriate, discuss ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award. Include a plan for resolving intellectual and material

property issues among participating organizations. If the intellectual property rights are not owned by the applicant, PI, or a member of the study team, describe the planned next steps necessary to make the product available to the target population.

- **Attachment 9: Animal Research Plan (five-page limit): Upload as "AnimalResPlan.pdf".** ***(Attachment 9 is only applicable and required for applications proposing animal studies.)***

  Proposed studies should not rely on samples, reagents, or tools that are contingent upon completion of other ongoing efforts outside the scope of this research project.

  If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the ARRIVE guidelines 2.0 (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:

  - Briefly describe the research objective(s) of the animal study.
  - If using an existing animal model, provide evidence that the chosen animal model(s) is validated and well-justified in the literature. If developing a novel animal model, explain how the animal model is expected to be superior to other existing models (if others exist) and indicate how this model will address the translational research study aims.
  - Include relevant preliminary data to support testing the study hypothesis in this animal model.
  - If applicable, describe approaches that will be undertaken to corroborate findings from animal studies to relevant human data sources/populations.
  - Summarize the procedures to be conducted. Describe how the study will be controlled.

- **Attachment 10: Human Subjects/Samples/Data Acquisition Plan (no page limit): Upload as "HumSubProc.pdf".** ***(Attachment 10 is only applicable and required for applications proposing research involving human subjects, human biological samples, or datasets.)***

  Proposed studies should not rely on samples, reagents, or tools that are contingent upon completion of other ongoing efforts outside the scope of this proposal.

  If the proposed study involves human subjects, human biological samples, or datasets, a summary describing the research that will be conducted must be included in the application and should address the following points:

  - Clearly state if the proposed study will utilize human samples or data that cannot be linked to a living individual and meet the requirements for exemption under 45 CFR 46.104(d)(4) of the Common Rule, Secondary Research for Which Consent is Not Required (typically classified as exempt from IRB review).
  - Describe the study population and explain how well it is designed to achieve the study objectives, including relevance of the population to the endpoints/outcome

measures. Describe how the study will be controlled. ***Applicants are strongly encouraged to use relevant military and/or Veteran populations/samples/ datasets.*** If a non-military population will be used for the proposed research project to simulate a military-related toxic exposure, explain how the population simulates the targeted population and how the results will benefit Service Members, their Families and/or Veterans.

- Describe the strategy for the inclusion of women and minorities appropriate to the study objectives, including the distribution of the proposed enrollment in terms of sex, racial, and ethnic group, and accompanying rationale (not applicable for IRB-exempt studies). Corresponding anticipated enrollment table(s) are required in Attachment 2.
- Provide an overview of the recruitment of human subjects and/or the acquisition of samples/datasets (i.e., the nature, methods, approximate number, pertinent demographic characteristics, inclusion/exclusion criteria).
- Describe the informed consent process, screening procedures and risk/benefit considerations (not applicable for IRB-exempt studies).
- Describe the types of samples/datasets to be collected and evaluated. Include information about sample storage and maintenance (i.e., location, duration, special handling conditions), if applicable.
- Describe potential limitations of datasets and/or data collection instruments and the impact on research endpoints.
- Describe the availability and feasibility of accessing the proposed study populations/ samples/datasets; past successes in recruiting and/or accessing similar populations/ samples/datasets; and plans to maintain access throughout the entire proposed research study.
- Address any potential barriers to subject retention and/or sample/data accrual, including access to the proposed study populations/samples. Provide mitigation plans for addressing unanticipated delays, including other ongoing studies competing for the same samples/populations, slow or low enrollment, or poor retention, as applicable.
- For studies involving Gulf War (GW) Veterans, the use of both the U.S. Centers for Disease Control and Prevention (CDC) and Kansas case definitions are required. Describe and justify any additional case definition of GWI, including any targeted illness subgroups that will be defined for the study. If proposing clinical research with GW Veterans, the use of the Common Data Elements (CDEs) for GWI Clinical Research is strongly encouraged. If applicable, describe how the use of GWI CDEs was considered when developing the plans for the collection of clinical data and annotation of clinical samples.

- **Attachment 11: Use of Hazardous Chemical or Biological Agents *(if applicable; no page limit)*: Upload as "Hazardous.pdf".** The applicant must submit a plan for acquiring, using, and maintaining hazardous agents if such agents are to be used in the study. The plan must contain all applicable information such as CDC registration, an approved organizational safety plan to use the agent(s), and letters of collaboration, agreement, or approval from government sites issuing any agent(s). Indicate whether agents used are purchased commercially, and, if so, confirm that the amount is under regulated limits. Include a statement addressing this requirement along with accompanying letters of collaboration, approvals and certifications.

- **Attachment 12: Study Personnel (two-page limit): Upload as "Personnel.pdf".**
  - Discuss the qualifications and experience/expertise of each research team, including each individual's level of effort, their role in project, and how they will contribute to the success of the proposed project.
  - Clearly state whether key personnel are not receiving salary from the respective award. If applicable, provide assurances/letters of commitment that the unpaid personnel will contribute the required level of effort to complete the project.
  - Describe the PIs' records of accomplishment and their ability to lead the research team to accomplish the proposed research project. Describe previous experience most pertinent to this project.
  - If a military or Veteran consumer(s) will be a member of the research team, describe how they will contribute to the development of the research question, project design, oversight, and evaluation, as well as any other significant aspects of the proposed project.
- **Attachment 13: Partnership Statement (one-page limit)** ***(Attachment 13 is only applicable and required for applications submitted under the Partnering PI Option):*** **Upload as "Partnership.pdf".**
  - Describe the interdisciplinary partnership, including how the combined unique expertise of the Initiating and Partnering PI will better address the research question.
  - Describe how the combined effort will be synergistic and produce an outcome greater than what could be achieved by independent efforts.
  - Outline the contribution and time commitment of each PI and how each will have appropriately balanced equal intellectual input on the design, conduct, and analysis of the project.
  - Describe how the PIs will manage the collaboration and workflow to optimize research efforts.
- **Attachment 14: Representations** ***(Grants.gov submissions only)*****: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.
- **Attachment 15: Suggested Intragovernmental/Intramural Budget Form** ***(if applicable)*****: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

 Grants.gov

 eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for the Partnering PI, or vice versa, even if they are located within the same organization. Refer to Section 3.4, Funding Details, for detailed budget information.

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.3.2. Full Application Components for the Partnering PI

Refer to the equivalent attachment above for details specific to each of the following application components. See Appendix 1 for a checklist of the full application components required for the Partnering PI.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov Submissions Only)*:

(b) Attachments:

- **Attachment 5: Statement of Work (six-page limit): Upload as "SOW.pdf".** Each PI must submit an identical copy of a jointly created SOW.
- **Attachment 14: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".**
- **Attachment 15: Suggested Intragovernmental/Intramural Budget Form: Upload as "IGBudget.pdf".**

(c) Additional Application Materials:

The following are additional application materials for application submission. Follow the instructions specific to the submission portal found within the GAI.

Grants.gov eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Partnering PI should not include budget information for the Initiating PI, or vice versa, even if they are located within the same organization. Refer to Section 3.4, Funding Details, for detailed budget information.

iii. Project/Performance Site Location(s) Form

iv. Research & Related Subaward Budget Attachment(s) Form *(if applicable, Grants.gov submissions only)*

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526TERPTRA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI or Initiating PI through eBRAP including the submission of contact information for the Partnering PI if selecting the Partnering PI Option.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

Partnering PI Option: After the Initiating PI confirms submission of the pre-application, the Partnering PI will be notified of the pre-application submission via an email from eBRAP. ***The Partnering PI must follow the instructions provided in the email to associate the partnering pre-application with their eBRAP account.*** If not previously registered, the Partnering PI must register in eBRAP.

Partnering PIs should not initiate a new pre-application based on the same research project submitted by the Initiating PI. Partnering PIs are urged to associate the partnering pre-application with their eBRAP account as soon as possible. If this is not completed by the full application deadline:

- Any intramural Partnering PI will not be able to submit their full application package components to eBRAP.
- The Partnering PI will not be able to view and modify their full application during the verification period in eBRAP.

When starting the pre-application, PIs should select a Mechanism Option appropriate to their pre-application:

Application Includes:	Select Mechanism Option:
Research by a **single PI**	Translational Research Award (TRA); select “no option”
Research by **two PIs**	Translational Research Award – Partnering PI Option (TRA – PPIO)

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission.

The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the application verification period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.

Members of the FY26 TERP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 TERP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

To determine the merits of the pre-application and the relevance to the mission of the TERP, pre-applications will be screened based on the following criteria:

- **Background and Rationale**
  - Whether the study rationale and hypothesis are well-supported and justified.
- **Specific Aims and Study Design**
  - How well the applicant states the specific aims, and whether the experimental approaches are clearly described.
  - If applicable, to what degree the proposed human populations/samples/datasets include Service Members, their Families, and/or Veterans; OR whether the proposed populations/samples/datasets are relevant to military-related toxic exposures and will benefit Service Members, their Families and/or Veterans.
- **Alignment**
  - How well the proposed project addresses at least one of the FY26 TERP Program Goals and at least one of the FY26 TERP Topic Areas.

- Whether the proposed project adheres to the intent of the FY26 TERP and is compliant with the program's Additional Guidance.

- **Translational Potential**
  - How well the project will accelerate the movement of promising ideas in military-related toxic exposure research into clinical application and advance the field forward along the translational research spectrum.
  - Whether the application integrates basic and clinical observations and allows for the reciprocal transfer of information between basic and clinical scientists.
- **Impact and Military Relevance**
  - To what degree the proposed research project will have both short- and long-term impacts, and how the successful completion of the project will advance the research field and ultimately lead to new treatments/therapeutics, diagnostic assays, or prevention strategies that improve the quality of life for those impacted by or likely to encounter toxic substances.
  - To what degree the proposed research is responsive to the health care needs of Service Members, their Families, and/or Veterans that have been or could potentially be exposed to military-related toxic exposures.
  - To what extent the research findings could benefit the general population.
- **Partnership *(applicable only to PPIO submissions)***
  - How well the proposed study describes the interdisciplinary partnership and how the collaborative efforts will better address the research question.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, of which **Research Strategy and Feasibility, Translational Potential**, **Impact and Military Relevance, and Personnel** are equally of most importance, with the remaining criteria of equal, but lesser, importance:

- **Research Strategy and Feasibility**
  - How well the application describes the scientific rationale for the study, including relevant preliminary data that support the feasibility of the proposed study, and a literature review that supports the development of the proposed project and provides the basis for the study questions and/or hypotheses.
  - Whether the hypothesis or objectives of the study are clearly stated, and how well the detailed specific aims are described and aligned with the tasks in the SOW.
  - How well the application describes the experimental design, methods, analyses, and models, including the appropriate controls; how well the approaches will meet the project's goals and milestones; and whether the project is feasible and can be completed within the proposed period of performance.
  - If applicable, how well the proposed correlative study complements the existing research efforts and provides additional relevant insight beyond the initial study design.
  - How thoroughly the application acknowledges potential research challenges and pitfalls, and provides alternative methods and approaches.

- For studies involving hazardous agents, whether the application includes an appropriate plan for acquiring, using, and maintaining the hazardous agents.
- If applicable, whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study, or whether the justification for a single-sex study is sufficiently strong.

Applicable to research involving cell line(s) and/or animals:

- How well the choice of proposed cell line(s) and/or animal model is justified and relevant to human biology (including, but not limited to, routes of human exposures, exposure dose, outcomes [human symptoms, diseases/conditions] associated with exposures, and types of exposures potentially encountered).
- If applicable, how well the animal study (or studies) is designed and controlled to achieve the objectives (including the choice of animal species, strain, and model) and the endpoints/outcome measures to be used.
- If applicable, whether appropriate approaches are being undertaken to corroborate findings from animal studies to human data sources/populations.

Applicable to research involving human subjects, samples and/or datasets:

- Whether the study population and the methods for recruitment of human subjects, or the acquisition of samples/datasets, are appropriate to accomplish the proposed work.
- Whether there is sufficient evidence provided to support the availability of/feasibility of accessing the proposed study populations/samples/datasets and past successes in recruiting/acquiring similar study populations/samples/datasets.
- How well the application addresses limitations of datasets and/or data collection instruments, and the impact on research endpoints.
- If applicable, whether the strategy for the inclusion of women and minorities and the distribution of proposed enrollment are appropriate for the proposed study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically those classified as exempt from IRB review) are exempt from this requirement.
- If applicable, to what degree the distribution of the proposed enrollment or dataset on the basis of sex, race, and/or ethnicity is appropriate and is related to the scientific goals of the proposed research.
- How well the application identifies any potential barriers to subject retention and/or sample/data accrual and provides mitigation plans for addressing unanticipated delays.
- Whether studies including GW Veterans use both the CDC and Kansas case definitions, and whether any additional case definitions of GWI are justified and well-defined for the study.
- For studies involving GW Veterans, to what extent the use of GWI CDEs was considered when developing the plans for the collection of clinical data and annotation of clinical samples.

- **Translational Potential**
  - How well the application describes and justifies the likelihood that the proposed research will move observations forward into clinical application and accelerate the introduction of health care products, interventions, technologies, or clinical practice guidelines.

- How well the proposed project allows for the reciprocal transfer of ideas between basic and clinical science.
- How well the application describes where the field is now (including the current state of knowledge or practice), and where the field will be after successful completion of the proposed research project.
- How well the application describes the timeframes of specific translation pathways for the proposed outcome(s)/product(s).

- **Impact and Military Relevance**
  - To what extent a successful outcome of the proposed research project will have an impact on military-related toxic exposure research and/or patient care, and will advance at least one of the FY26 TERP Program Goals and at least one of the FY26 TERP Topic Areas.
  - To what extent a successful outcome of the proposed research project will reduce the burden (effects/outcomes, new exposures, etc.) of military-related toxic exposures for Service Members, their Families, Veterans and/or the American public.
  - Whether the anticipated short-term outcome(s)/products (intellectual knowledge and/or tangible materiel) will make an important scientific advancement and improve the understanding, prevention/prediction, diagnosis, and/or treatment of military-related toxic exposures.
  - Whether the anticipated long-term benefits will impact the field of study and/or the lives of relevant patient or community populations, and whether the anticipated outcomes will benefit the clinic or the field.
  - Whether the application describes the near-term and long-term impact of the translation pathways for the proposed outcome(s)/product(s).
  - To what extent the proposed materiel or knowledge product represents an improvement to currently available prevention or treatments/interventions, diagnostic approaches, devices, or clinical practice guidelines (if applicable).
  - How well the proposed effort is responsive to the health care needs and quality of life of Service Members, their Families and/or Veterans.
  - Whether the application provides a description of how the knowledge, information, products, or technologies gained from the research could be implemented in a dual-use capacity to benefit the civilian population and address military needs (as appropriate).
  - If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Personnel**
  - Whether the levels of effort of the PI and other key personnel are appropriate for ensuring the success of the project.
  - To what degree the qualifications and experience/expertise of each research team, including each individual's role, will contribute to the success of the proposed project.
  - Whether the application clearly describes the PIs' records of accomplishment and their ability to lead the research team to accomplish the proposed research project, and to what degree their previous experience most pertinent to this project is sufficient to achieve the project's goals.

Applicable for applications submitted to the Partnering PI Option:

- To what degree the interdisciplinary partnership and combined unique expertise of the Initiating and Partnering PI will better address the research question together rather than through separate individual efforts.
- How well the application reflects that all PIs provided an appropriately balanced intellectual input into the design of the project.

- **Post-Award Transition Plan**
  - How well the application describes the methods and strategies that will be used to advance the anticipated research outcomes/products (intellectual knowledge and/or tangible materiel) to the next phase of development (clinical trials, commercialization, and/or delivery to the civilian or military market) following the completion of the proposed effort.
  - Whether the outcomes/products expected following the completion of the proposed research are well described, relevant, and measurable, and whether the application discusses the intended end-user.
  - How well the application describes the funding strategy that will be used to advance the outcomes to the next phase of development, commercialization (e.g., partners, funding opportunities to be applied for), and/or to incorporate them into patient care.
  - To what extent the milestones for bringing the outcomes/products to the next phase of development (further research, clinical trials, commercialization/transition to industry, delivery to the military or civilian market, incorporation into clinical practice, clearance/approval by a Regulatory Agency) are described.
  - To what degree the application considers and addresses the ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award in planning.
  - How well the application describes how the anticipated outcomes/products of the proposed research will be disseminated to both the scientific and consumer/stakeholder communities.
- **Statistical Plan and Data Analysis**
  - Whether the application provides a description of how the data will be handled and statistically analyzed.
  - How well the application explains the statistical model and data analysis plan, and whether they are appropriate for the proposed study objectives.
  - Whether the application identifies rules for stopping data collection and criteria for inclusion and exclusion of data, and describes how outliers will be defined and handled.
  - If applicable, to what extent the statistical plan and sample size, including power analysis, are appropriate for the study objectives.
  - If applicable, whether the randomization and blinding procedures for the study are appropriate and discuss other measures taken to minimize the effects of subjective bias.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Research Sharing Plan**
  - To what extent the plan for sharing project data and research resources is appropriate and reasonable, and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be archived.
- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 TERP, as evidenced by the following:
  - Adherence to the intent of the funding opportunity
  - Program portfolio composition and balance
  - Relative impact and military relevance

6.3. Application Review and Selection Process

6.3.1. Pre-Application

Following the pre-application screening, PIs will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in Section 1, Basic Information About the Funding Opportunity. No feedback (e.g., a critique of the pre-application's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the TERP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), Institutional Review Board (IRB) or Ethics Committee (EC) review.

8.2. Reporting

Annual technical progress reports and quad charts, as well as a final technical progress report and quad chart, will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan, using the template available on eBRAP, must be submitted with the final progress report.

PHS Inclusion Enrollment Reporting *(required for research proposing clinical research and/or clinical trials)*: Enrollment reporting on the basis of sex, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of pre-applications and full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- Submission of an application for which a letter of invitation was not issued.
- The Project Narrative is missing.
- The Budget is missing.
- Post-Award Transition Plan (Attachment 8) is missing.
- Partnership Statement (Attachment 13) is missing for TRA – PPIO applications.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 TERP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.

- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- Failure to submit all associated (Initiating and Partnering PI) applications by the deadline (for TRA – PPIO applications).
- The PI, or the Initiating and/or Partnering PI (for TRA – PPIO applications) does not meet the eligibility criteria.
- The applicant is named as a PI on more than one application to the TERP.
- The invited application proposes a different research project than that described in the pre-application.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- A clinical trial is proposed.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded	
	PI/Initiating PI	Partnering PI
SF424 Research & Related Application for Federal Assistance *(Grants.gov submissions only)*	☐	☐
Summary (Tab 1) and Application Contacts (Tab 2) *(eBRAP submissions only)*	☐	☐
Attachments		
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐	
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐	
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐	
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐	
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐	☐
Translation Statement – Attachment 6, upload as "Translation.pdf"	☐	
Impact and Military Relevance – Attachment 7, upload as "Impact.pdf"	☐	
Post-Award Transition Plan – Attachment 8, upload as "Transition.pdf"	☐	
Animal Research Plan *(if applicable)* – Attachment 9, upload as "AnimalResPlan.pdf"	☐	
Human Subjects/Samples/Data Acquisition Plan *(if applicable)* – Attachment 10, upload as "HumSubProc.pdf"		
Use of Hazardous Chemical or Biological Agents *(if applicable)* – Attachment 11, upload as "Hazardous.pdf"	☐	
Study Personnel – Attachment 12, upload as "Personnel.pdf"	☐	
Partnership Statement *(if applicable)* – Attachment 13, upload as "Partnership.pdf"	☐	
Representations *(Grants.gov submissions only)* – Attachment 14, upload as "RequiredReps.pdf"	☐	☐
Suggested Intragovernmental Budget Form *(if applicable)* – Attachment 15, upload as "IGBudget.pdf"	☐	☐
Additional Application Materials		
Research & Related Senior/Key Person Profile (Expanded)	☐	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐	☐

Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐	☐
Research & Related Budget	☐	☐
Project/Performance Site Location(s)	☐	☐
Research & Related Subaward Budget Attachment(s) (*if applicable)*	☐	☐

Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting of In Vivo Experiments
CDC	U.S. Centers for Disease Control and Prevention
CDE	Common Data Element
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
GAI	General Application Instructions
GW	Gulf War
GWI	Gulf War Illness
GWIRP	Gulf War Illness Research Program
IACUC	Institutional Animal Care and Use Committee
IRB	Institutional Review Board
LAR	Legally Authorized Representative
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
PPIO	Partnering Principal Investigator Option
ROC	Roles of Care, Role of Care
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)

STROBE	STrengthening the Reporting of OBservational studies in Epidemiology
SOW	Statement of Work
TERP	Toxic Exposures Research Program
TRA	Translational Research Award
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs

Appendix 3. TERP Definitions

The TERP uses the following definitions:

- **Fourth Generation Agents:** "Fourth generation agents, also known as Novichoks or A-series nerve agents, belong to a category of chemical warfare agents that are unique organophosphorus compounds. They are more persistent than other nerve agents and are at least as toxic as VX."
- **Gulf War (GW):** The 1990-1991 Persian Gulf War.
- **Gulf War Illness (GWI):**
    - **Case Definitions:** In 2014, the Institute of Medicine (IOM) (now called National Academy of Medicine) released a report, "Chronic Multisymptom Illness in Gulf War Veterans: Case Definitions Reexamined." In this report, the IOM recommended the use of both the CDC definition of GWI and the "Kansas" definition of GWI. Applicants are encouraged to review this report, as the use of these case definitions is required when proposing clinical research/clinical trials with GW Veterans. Additional information on GWI can also be found in the 2014 report from the Research Advisory Committee on Gulf War Veterans' Illnesses, "Gulf War Illness and the Health of Gulf War Veterans: Research Update and Recommendations, 2009-2013."
    - The former DOD CDMRP GWIRP assembled multiple resources that applicants may find helpful if proposing studies on GWI.
    - **Common Data Elements for GWI Clinical Research:** Through a collaboration among the NIH, CDC, VA, former DOW CDMRP GWIRP, and the GWI community, CDE recommendations were developed for GWI. Applicants proposing clinical research under the topic area of "Gulf War Illness and Its Treatment" are strongly encouraged to review and consider the CDEs when preparing applications. Information on the GWI CDEs can be found on the GWIRP website and in: Cohen DE, Sullivan KA, McNeil RB, et al. 2022. "A common language for Gulf War Illness (GWI) research studies: GWI common data elements." *Life Sciences Journal* 290:119818. doi:10.1016/j.lfs.2021.119818.
- **Medical Countermeasures:** Medicines and medical products that can be used to diagnose, prevent, or treat diseases/conditions/symptoms related to chemical, biological, radiological, or nuclear (CBRN) threats.
- **Military-Related Toxic Exposures:** Exposures to known or unknown, naturally occurring or manmade substances associated with deployed, garrison, or other military-linked environments, that result in adverse health effects. For the purposes of this TERP program announcement, exposures solely focused on environmental extremes are not considered military-related toxic exposures.
- **New Approach Methodologies:** "Technologies and approaches that can potentially provide the same hazard and risk assessment information without the use of animal testing."
- **Neurotoxin:** Synthetic or natural substances that damage, destroy, or impair the functioning of the nervous system.
- **Non-Traditional Agents:** "Novel chemical threat agents or toxicants requiring adapted countermeasures."
- **Roles of Medical Care:** "The characterization of health support for the distribution of medical resources and capabilities." For more information on the military roles of care, refer

to Chapter 2, "Roles of Medical Care (United States)," Emergency War Surgery, Fifth United States Edition, 2018, Borden Institute.

- **Toxicant:** "A poison that is made by humans or that is put into the environment by human activities."
- **Toxic Exposures:** Exposures to known and unknown naturally occurring or manmade, harmful substances that result in adverse health effects.

Appendix 4. Resources for Data and/or Previously Collected Biospecimens

Boston Biorepository, Recruitment, and Integrated Network for GWI (BBRAIN)
DHA Data Sharing Agreements
Defense Manpower Data Center (DMDC)
Defense Medical Surveillance System (DMSS)
Defense Occupational and Environmental Health Readiness System (DOEHRS)
DOD Serum Repository (DODSR)
Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC)
Individual Longitudinal Exposure Record (ILER)
Massachusetts Veterans Epidemiology Research and Information Collaborative (MAVERIC)
Millennium Cohort Study
Million Veteran Program (MVP)
Red Hill Bulk Fuel Storage Facility Information
Red Hill Fuel Release Public Health Information
VA Environmental Health Registries
VA Gulf War Veterans' Illnesses Biorepository Brain Bank (GWVIB)
VA Gulf War Era Cohort and Biorepository (GWECB)